4.5 Article

Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival

Journal

EUROPEAN JOURNAL OF RADIOLOGY
Volume 84, Issue 5, Pages 998-1004

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ejrad.2015.01.021

Keywords

Interstitial lung disease; Lung cancer; Computed tomography; Advanced non-small-cell lung cancer; Survival

Funding

  1. National Institutes of Health [1K23CA157631, 1RO1CA114465-07, 5R21CA11627-02]
  2. National Cancer Institute Specialized Program of Research Excellence in Lung Cancer [2P50CA090578-10]
  3. Genentech Inc
  4. Doris and William Krupp Research Fund in Thoracic Oncology
  5. Gallup Fund in Thoracic Oncology
  6. American Society of Clinical Oncology Translational Research Professorship

Ask authors/readers for more resources

Objective: Interstitial lung diseases are associated with increased risk of lung cancer. The prevalence of ILA at diagnosis of advanced non-small-cell lung cancer (NSCLC) and its impact on overall survival (OS) remain to be investigated. Materials and method: The study included 120 treatment-naive stage IV NSCLC patients (53 males, 67 females). ILA was scored on CT prior to any systemic therapy using a 4-point scale [0 = no evidence of ILA, 1 = equivocal for ILA, 2 = suspicious for ILA, 3 = ILA] by a sequential reading method previously reported. ILA scores of 2 or 3 indicated the presence of ILA. Results: ILA was present in 17 patients (14%) with advanced NSCLC prior to any treatment (score3: n = 2, score2: n = 15). These 17 patients were significantly older (median age: 69 vs. 63, p = 0.04) and had a heavier smoking history (median: 40 vs. 15.5 pack-year, p = 0.003) than those with ILA score 0 or 1. Higher ILA scores were associated with shorter OS (p = 0.001). Median OS of the 17 patients with ILA was 7.2 months [95%CI: 2.9-9.4] compared to 14.8 months [95%CI: 11.1-18.4] in patients with ILA score 0 or 1 (p = 0.002). In a multivariate model, the presence of ILA remained significant for increased risk for death (HR = 2.09, p = 0.028) after adjusting for first-line systemic therapy (chemotherapy, p < 0.001; TKI, p < 0.001; each compared to no therapy) and pack years of smoking (p = 0.40). Conclusion: Radiographic ILA was present in 14% of treatment-naive advanced NSCLC patients. Higher ILA scores were associated with shorter OS, indicating that ILA could be a marker of shorter survival in advanced NSCLC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available